Infarto agudo de miocardio. SCACEST

  1. García Sebastián, C. 1
  2. Abellas Sequeiros, M. 1
  3. Monteagudo Ruiz, J.M. 1
  4. Zamorano Gómez, J.L. 1
  1. 1 Servicio de Cardiología, Hospital Universitario Ramón y Cajal, Madrid, España
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Año de publicación: 2021

Título del ejemplar: Enfermedades cardiovasculares (IV)

Serie: 13

Número: 38

Páginas: 2177-2184

Tipo: Artículo

DOI: 10.1016/J.MED.2021.07.002 DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Medicine: Programa de Formación Médica Continuada Acreditado

Objetivos de desarrollo sostenible

Resumen

El síndrome coronario agudo (SCA) se produce cuando existe un desequilibrio entre la demanda y el aporte de oxígeno al miocardio. Cuando este SCA se acompaña de elevación del segmento ST (SCACEST), habitualmente se debe a la rotura de una placa de ateroma con formación de trombo que produce oclusión aguda de la arteria coronaria. La presentación clínica más frecuente del SCACEST es la de dolor centrotorácico opresivo persistente y elevación del segmento ST en el electrocardiograma. Sin embargo, en ocasiones se pueden observar manifestaciones clínicas o electrocardiográficas atípicas que complican el diagnóstico y pueden retrasar la instauración del tratamiento. El desarrollo de sistemas estructurados de atención al SCACEST (código infarto) es fundamental para asegurar la calidad asistencial y reducir los tiempos hasta el tratamiento. El tratamiento se basa en la revascularización con apertura del vaso afecto, mediante dos técnicas: angioplastia primaria (de elección) o fibrinólisis. La prevención secundaria y la participación en programas de rehabilitación cardíaca son elementos clave en el tratamiento a largo plazo de estos pacientes.

Referencias bibliográficas

  • Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA. Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. Fourth Universal Definition of Myocardial Infarction (2018). J Am Coll Cardiol. 2018;72(18):2231-64.
  • Ibáñez B, James S, Agewall S, Antunes MJ, Bucciarelli Ducci C, Bueno H. ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119-77.
  • Scirica BM, Libby P, Morrow DA. Infarto de miocardio con elevación del segmento ST: fisiopatología y evolución clínica. En: Zipes DP, Libby P, Bonow RO, Mann DL, Tomaselli GF, Braunwald E, eds. Tratado de cardiología. 11ª ed. Barcelona: Elsevier; 2019. p. 1095-122.
  • Gharacholou SM, Alexander KP, Chen AY, Wang TY, Melloni C, Gibler WB. Implications and reasons for the lack of use of reperfusion therapy in patients with ST-segment elevation myocardial infarction: findings from the CRUSADE initiative. Am Heart J. 2010;159(5):757-63.
  • Monsieurs KG, Nolan JP, Bossaert LL, Greif R, Maconochie IK, Nikolaou NI. European Resuscitation Council Guidelines for Resuscitation 2015: Section 1. Executive summary. Resuscitation. 2015;95:1-80.
  • Hypothermia after Cardiac Arrest Study Group. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med. 2002;346(8):549-56.
  • O’Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013; 61(4):e78-e140.
  • Sgarbossa EB, Pinski SL, Barbagelata A, Underwood DA, Gates KB, Topol EJ. Electrocardiographic diagnosis of evolving acute myocardial infarction in the presence of left bundlebranch block. GUSTO-1 (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries) Investigators. N Engl J Med. 1996;334(8): 481-7.
  • Sgarbossa EB, Pinski SL, Gates KB, Wagner GS. Early electrocardiographic diagnosis of acute myocardial infarction in the presence of ventricular paced rhythm. GUSTO-I investigators. Am J Cardiol. 1996;77(5):423-4.
  • Yan AT, Yan RT, Kennelly BM, Anderson FA Jr, Budaj A, López Sendón J., GRACE Investigators. Relationship of ST elevation in lead aVR with angiographic findings and outcome in non-ST elevation acute coronary syndromes. Am Heart J. 2007;154(1):71-8.
  • Wagner GS. Marriott: electrocardiografía práctica. 11ª ed. Barcelona: Lippincott Williams & Wilkins: 2008.
  • Townsend N, Wilson L, Bhatnagar P, Wickramasinghe K, Rayner M, Nichols M. Cardiovascular disease in Europe: epidemiological update 2016. Eur Heart J. 2016;37(42):3232-45.
  • Cabello JB, Burls A, Emparanza JI, Bayliss S, Quinn T. Oxygen therapy for acute myocardial infarction. Cochrane Database Syst Rev 2013;8:CD007160.
  • Fordyce CB, Al-Khalidi HR, Jollis JG, Roettig ML, Gu J, Bagai A. STEMI Systems Accelerator Project. Association of rapid care process implementation on reperfusion times across multiple ST-segment elevation myocardial infarction networks. Circ Cardiovasc Interv. 2017;10(1): e004061.
  • Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003;361(9351): 13-20.
  • Kastrati A, Dibra A, Spaulding C, Laarman GJ, Menichelli M, Valgimigli M. Meta analysis of randomized trials on drug eluting stents vs. baremetal stents in patients with acute myocardial infarction. Eur Heart J. 2007;28(22):2706-13.
  • De Luca G, Smits P, Hofma SH, Di Lorenzo E, Vlachojannis GJ, Van’t Hof AWJ. Drug Eluting Stent in Primary Angioplasty (DESERT 3) cooperation. Everolimus eluting stent vs first generation drug eluting stent in primary angioplasty: A pooled patient level meta analysis of randomized trials. Int J Cardiol. 2017;244:121-7.
  • Elgendy IY, Mahmoud AN, Kumbhani DJ, Bhatt DL, Bavry AA. Complete or culprit only revascularization for patients with multivessel coronary artery disease undergoing percutaneous coronary intervention: a pairwise and network meta analysis of randomized trials. JACC Cardiovasc Interv. 2017;10(4):315-24.
  • Schüpke S, Neumann FJ, Menichelli M, Mayer K, Bernlochner I, Wöhrle J. ISAR-REACT 5 Trial Investigators. Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med. 2019;381(16):1524-34.
  • Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB. OASIS-6 Trial Group. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA. 2006;295(13):1519-30.
  • Morrison LJ, Verbeck PR, McDonald AC, Sawadsky BV, Cook DJ. Mortality and prehospital thrombolysis for acute myocardial infarction: a meta analysis. JAMA 2000;283(20):2686-92.
  • Van de Werf F, Adgey J, Ardissino D, Armstrong PW, Aylward P, Barbash G. Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators. Single bolus tenecteplase compared with front loaded alteplase in acute myocardial infarction: the ASSENT-2 double blind randomised trial. Lancet 1999;354(9180):716-22.
  • Van de Werf F, Barron HV, Armstrong PW, Granger CB, Berioli S, Barbash G. ASSENT-2 Investigators, Assessment of the safety and efficacy of a new thrombolytic. Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin specific agents: a comparison of TNK-tPA and rt-PA. Eur Heart J 2001;22(24):2253-61.
  • Anderson L, Oldridge N, Thompson DR, Zwisler AD, Rees K, Martin N. Exercise based cardiac rehabilitation for coronary heart disease: Cochrane systematic review and meta analysis. J Am Coll Cardiol. 2016;67(1):1-12.
  • Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L. ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-88.
  • Fox KA, Fitzgerald G, Puymirat E, Huang W, Carruthers K, Simon T. Should patients with acute coronary disease be stratified for management according to their risk? Derivation, external validation and outco-mes using the updated GRACE risk score. BMJ Open. 2014;4:e004425.
Fuente de los datos: Dialnet